771-28-8

Basic information

• Product Name: N'-HYDROXY-2-METHOXYBENZENECARBOXIMIDAMIDE
• Synonyms: (Z)-N-Hydroxy-2-MethoxybenziMidaMide;2-Methoxybenzamidoxime
• CAS NO: 771-28-8
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1811
• Mol File: 771-28-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 115-116 °C
• Boiling Point: 298.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.63±0.50(Predicted)
• CAS DataBase Reference: N'-HYDROXY-2-METHOXYBENZENECARBOXIMIDAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N'-HYDROXY-2-METHOXYBENZENECARBOXIMIDAMIDE(771-28-8)
• EPA Substance Registry System: N'-HYDROXY-2-METHOXYBENZENECARBOXIMIDAMIDE(771-28-8)

Safety Data

• Hazardous Substances Data: 771-28-8(Hazardous Substances Data)

Usage

General Description

N'-HYDROXY-2-METHOXYBENZENECARBOXIMIDAMIDE, also known as ortalan, is a chemical compound with the molecular formula C8H8N2O3. It belongs to the class of carboxylic acid derivatives and is used in pharmaceutical research as a substrate for the inhibition of aldose reductase, an enzyme that is involved in the development of diabetic complications. Ortolan has also been studied for its potential application in cancer treatment, as it has shown inhibitory effects on cancer cell growth. Additionally, it is utilized in the synthesis of organic compounds and has been investigated for its antioxidant properties. This chemical compound is considered to have potential therapeutic applications in various fields, including diabetes and cancer research.

Upstream product

• 71590-96-0 2-hydroxy-6-methoxybenzonitrile 
• 6609-56-9 2-methoxy-benzonitrile 
• 64-17-5 ethanol 

Downstream Products

• 144726-82-9 3-(2-methoxyphenyl)-5-phenyl-1,2,4-oxadiazole 
• 131012-96-9 3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-azabicyclo[2.2.2]octane 
• 75907-92-5 O-(4,4-Dinitropentanoyl)-2-methoxybenzamidoxime 
• 844498-72-2 C₁₀H₁₁ClN₂O₃ 
• 110704-43-3 5-Chloromethyl-3-(2-methoxy-phenyl)-[1,2,4]oxadiazole 
• 110722-46-8 {3-[3-(2-Methoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid 
• 138129-01-8 {3-[3-(2-Methoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid ethyl ester 
• 75908-02-0 5-(3,3-Dinitrobutyl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole 
• 1140460-76-9 1-{4-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-nitrophenyl}piperidine 
• 1166828-81-4 5-[5-ethyl-1-(2-fluorophenyl)-1H-1,2,3-triazole-4-yl]-3-(2-methoxyphenyl)-1,2,4-oxadiazole 
• 1166828-86-9 4-{1-(2-fluorophenyl)-4-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-triazol-5-yl}pyridine 
• 1001467-29-3 C₁₉H₂₅N₃O₄ 
• 1424313-59-6 2-(2-methoxyphenyl)-5-oxo-5H-chromeno[4,3-d]pyrimidine-3-oxide 
• 1443017-22-8 5-(4-fluorophenyl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole 

Relevant articles and documents

Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist

Diabetes is a ubiquitously a metabolic disorder and life-threatening disease. Peroxisome proliferator-activated receptors (PPARs) belong to the class of nuclear receptors which acts as transcription factors to regulate lipid and glucose metabolism. PPAR alpha/gamma dual agonists tend to corroborate the functions of both thiazolidinediones and fibrates and they hold substantial promise for ameliorating the type 2 diabetic treatments and providing potential therapeutic diabetic interventions. New 1,2,4-oxadiazole based trans- acrylic acid derivatives compounds possessing aryl/methylene linker in between pharmacophore head and lipophilic tail for dual PPAR-alpha/gamma agonists are studied. AutoDock Vina used for potential PPAR alpha/gamma dual agonists and 6 compounds 9a, 9g, 9 m, 9n, 9o, and 9r were identified comparable to PPAR gamma agonist Pioglitazone on the basis of their affinity scores and further their in-silico toxicity and in-silico ADME properties. The selected compounds showed better-calculated lipophilicity (iLogP) was found to be 0.92 to 3.19. Compound 9n and 9a were found to be most potent on both PPAR alpha and gamma receptors with EC50 of 0.07 ± 0.0006 μM, 0.06 ± 0.0005 μM and 0.781 ± 0.008 μM, 3.29 μM ± 0.03 respectively as better to pioglitazone having EC50 of 32.38 ± 0.2 and 38.03 ± 0.13 for both receptors. The in-vivo evaluation found to reduce the plasma glucose level and total cholesterol level significantly in diabetic rats compared to pioglitazone at 5 mg/kg/day dose for 7 days of treatment. Thus, trans- acrylic acid derivatives can be further developed as oral therapeutic agents for diabetic interventions as PPAR alpha/gamma dual agonists.

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep-Promoting Properties in Rats

The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline our optimization efforts toward a novel DORA. We started our investigation with rac-[3-(5-chloro-benzooxazol-2-ylamino)piperidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone (3), a structural hybrid of suvorexant and a piperidine-containing DORA. During the optimization, we resolved liabilities such as chemical instability, CYP3A4 inhibition, and low brain penetration potential. Furthermore, structural modification of the piperidine scaffold was essential to improve potency at the orexin 2 receptor. This work led to the identification of (5-methoxy-4-methyl-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone (51), a potent, brain-penetrating DORA with in vivo efficacy similar to that of suvorexant in rats.

AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to